Meng Zhang,1,2,* Xiuxiu Tan,1,* Junjie Huang,3,* Lijuan Xie,1 Hao Wang,1 Jizhou Shi,4 Wei Lu,1 Zhaojie Lv,1 Hongbing Mei,1 Chaozhao Liang21Department of Urology, Shenzhen Second People’s Hospital, Clinical Medicine of Anhui Medical University, 2Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, 3Department of Hematology, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 4Department of Urology, Shengli Oilfield Central Hospital, Dongying, Peoples Republic of China *These authors contributed equally to this workBackground: Several epidemiological studies have illustrated that polymorphisms in interleukin-2 (IL-2) were associated with diverse cancer types. However, recently published statistics were inconsistent and inconclusive. Therefore, the current meta-analysis was performed to elaborate the effects of IL-2 polymorphisms (rs2069762 and rs2069763) on cancer susceptibility.Material and methods: A total of 5,601 cancer cases and 7,809 controls from 21 published case–control studies were enrolled in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between IL-2 polymorphisms and cancer susceptibility.Results: Our study demonstrated an increased susceptibility to cancer in rs2069762 (G vs T: OR =1.268, 95% CI =1.113–1.445; GG vs TT: OR =1.801, 95% CI =1.289–2.516; GT vs TT: OR =1.250, 95% CI =1.061–1.473; GG + GT vs TT: OR =1.329, 95% CI =1.118–1.579; GG vs GT + TT: OR =1.536, 95% CI =1.162–2.030). In the subgroup analysis, increased susceptibility to cancer was identified in the hospital-based group and PHWE